BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8249381)

  • 1. [Aztreonam--new antibiotic for treating infections caused by gram-negative aerobic bacteria].
    Szymkowiak J; Fojt E
    Wiad Lek; 1993; 46(1-2):56-61. PubMed ID: 8249381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD; Jehl F; Froehly S; Dupeyron JP; Monteil H; Rosset MA
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
    Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
    Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aztreonam in lower respiratory tract infections.
    Cook JL
    Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
    Honderlick P; Gravisse J; Dardelle D; Cahen P
    Pathol Biol (Paris); 2007 Dec; 55(10):475-7. PubMed ID: 17904768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
    Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
    Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiology and pharmacology of aztreonam.
    Duma RJ
    Urology; 1988 Jun; 31(6 Suppl):9-13. PubMed ID: 3287750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of aztreonam in pediatric patients: a review.
    Bosso JA; Black PG
    Pharmacotherapy; 1991; 11(1):20-5. PubMed ID: 1902290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aztreonam in treatment of intra-abdominal infections.
    Malangoni MA
    Urology; 1988 Jun; 31(6 Suppl):28-32. PubMed ID: 3287747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides, imipenem, and aztreonam.
    Johnson JG; Hardin TC
    Clin Podiatr Med Surg; 1992 Apr; 9(2):443-64. PubMed ID: 1586911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital].
    Martínez B; Gómez J; Gómez Vargas J; Gómez JR; Baños V; Sánchez ME; Canteras M; Valdés M
    Rev Esp Quimioter; 2000 Jun; 13(2):187-92. PubMed ID: 10918093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam: the first monobactam.
    Neu HC
    Med Clin North Am; 1988 May; 72(3):555-66. PubMed ID: 3280906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam, a new monobactam antimicrobial.
    Guay DR; Koskoletos C
    Clin Pharm; 1985; 4(5):516-26. PubMed ID: 3902330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Necrotizing soft tissue infections: role of the localization for the antibiotic management].
    Wattel F; Mathieu D; Neut C; Dubreuil L; Cesari JF; Favory R
    Bull Acad Natl Med; 2004; 188(3):473-86; discussion 486-90. PubMed ID: 15584657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aztreonam.
    Johnson DH; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):733-43. PubMed ID: 7791420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.